---
title: "Obefazimod (ABX464) in Ulcerative colitis: ABX464-908"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: ABX464-908. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Statistical analysis description, and 2 further headings. 13 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence/abx464-908"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: ABX464-908

<a id="heading-3.1.12"></a>

## 3.1.12 ABX464-908

<a id="heading-3.1.12.1"></a>

### 3.1.12.1 Objective

<a id="topic-3.1.12.1-1"></a>

#### Purpose stated in the EU register title

> “A Phase I study to evaluate the pharmacokinetics, safety, and tolerability of multiple oral doses of obefazimod in patients with mild and moderate hepatic impairment, compared to matched control groups.”

Source: [EU Clinical Trials Information System 2023-505299-31-00](https://euclinicaltrials.eu/ctis-public/view/2023-505299-31-00)

<a id="topic-3.1.12.1-2"></a>

#### Purpose stated in the Form 20-F

> “a trial in participants with mild and moderate hepatic impairment compared to matched control normal liver function participants, for the purposes of assessing pharmacokinetics, safety and tolerability in this population”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.12.2"></a>

### 3.1.12.2 Location and Study Date

<a id="topic-3.1.12.2-1"></a>

#### Trial dates and status in the EU register

| Field | Register entry |
| --- | --- |
| Protocol code | “Protocol code: ABX464-908” |
| Location | “Locations Germany” |
| Start of trial | “Start of trial 09/10/2023” |
| End of trial | “End of trial 11/09/2024” |

Source: [EU Clinical Trials Information System 2023-505299-31-00](https://euclinicaltrials.eu/ctis-public/view/2023-505299-31-00)

<a id="topic-3.1.12.2-2"></a>

#### Trial site

> “CRS Clinical Research Services Management GmbH”

Source: [CTIS.eu 2023-505299-31-00](https://ctis.eu/trial/2023-505299-31-00)

<a id="heading-3.1.12.3"></a>

### 3.1.12.3 Study Design

<a id="topic-3.1.12.3-1"></a>

#### Phase 1 multiple-dose design with matched controls

> “Trial Phase Human Pharmacology (Phase I)- Other”
> “multiple oral doses of obefazimod in patients with mild and moderate hepatic impairment, compared to matched control groups”

Source: [EU Clinical Trials Information System 2023-505299-31-00](https://euclinicaltrials.eu/ctis-public/view/2023-505299-31-00)

<a id="heading-3.1.12.4"></a>

### 3.1.12.4 Eligibility Criteria

<a id="topic-3.1.12.4-1"></a>

#### Participant type and age in the EU register

| Field | Register entry |
| --- | --- |
| Participants type | “Participants type Patients” |
| Age range | “Age range 65+ years, 18-64 years” |

Source: [EU Clinical Trials Information System 2023-505299-31-00](https://euclinicaltrials.eu/ctis-public/view/2023-505299-31-00)

<a id="topic-3.1.12.4-2"></a>

#### Hepatic impairment groups and controls

> “participants with mild and moderate hepatic impairment compared to matched control normal liver function participants”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.12.5"></a>

### 3.1.12.5 Treatment

<a id="topic-3.1.12.5-1"></a>

#### Multiple oral doses of obefazimod

> “multiple oral doses of obefazimod”

Source: [EU Clinical Trials Information System 2023-505299-31-00](https://euclinicaltrials.eu/ctis-public/view/2023-505299-31-00)

<a id="heading-3.1.12.6"></a>

### 3.1.12.6 Study Outcomes

<a id="heading-3.1.12.6.1"></a>

#### 3.1.12.6.1 Rationale for Using Obefazimod Pharmacokinetics in Hepatic Impairment as the Study Endpoint

No evidence found.

<a id="heading-3.1.12.7"></a>

### 3.1.12.7 Statistical Analysis Description

<a id="heading-3.1.12.7.1"></a>

#### 3.1.12.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.12.7.1-1"></a>

##### Planned participants in the EU register

> “Germany: Ended. Planned participants: 32”

Source: [CTIS.eu 2023-505299-31-00](https://ctis.eu/trial/2023-505299-31-00)

<a id="topic-3.1.12.7.1-2"></a>

##### Enrollment stated in the Form 20-F

> “for which we enrolled 30 participants”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.12.7.2"></a>

#### 3.1.12.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.12.8"></a>

### 3.1.12.8 Results

<a id="heading-3.1.12.8.1"></a>

#### 3.1.12.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.12.8.2"></a>

#### 3.1.12.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.12.8.3"></a>

#### 3.1.12.8.3 Efficacy Results

<a id="topic-3.1.12.8.3-1"></a>

##### Company statement on the completed Phase 1 trials

> “The results of these Phase 1 clinical trials provide supportive data for our further clinical development and New Drug Application (“NDA”) submission.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.12.8.4"></a>

#### 3.1.12.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.12.8.5"></a>

#### 3.1.12.8.5 Safety Results

No evidence found.

<a id="heading-3.1.12.9"></a>

### 3.1.12.9 Study Limitations

<a id="topic-3.1.12.9-1"></a>

#### Summary

ABX464-908 has only an EU register record and a sentence in the Form 20-F. The register gives the title, the dates (9 October 2023 to 11 September 2024), one site in Germany, and 32 planned participants; the 20-F reports 30 enrolled participants with mild or moderate hepatic impairment or matched normal liver function. The 20-F states that the trial was completed in 2025, whereas the register gives 11 September 2024 as its end. The classification method for hepatic impairment, the dose, the number per group, and the endpoints are not public, severe hepatic impairment was not studied, and the summary of results is deferred until 11 March 2027. The 20-F describes the results only as “supportive data” for the NDA, so no exposure ratio or safety result is available to inform dosing in hepatic impairment.

Source: [EU Clinical Trials Information System 2023-505299-31-00](https://euclinicaltrials.eu/ctis-public/view/2023-505299-31-00); [CTIS.eu 2023-505299-31-00](https://ctis.eu/trial/2023-505299-31-00); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-3.1.12.9-2"></a>

#### Results publication deferred in the EU register

> “Summary of the results: deferred: adult category 1 trial (mostly phase I), results to be published from 11 Mar 2027 (EMA/263067/2023).”

Source: [CTIS.eu 2023-505299-31-00](https://ctis.eu/trial/2023-505299-31-00)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
